This Viewpoint uses results of randomized clinical trials to explore whether the use of abiraterone acetate plus prednisone is a cost-effective and appropriate treatment option for patients with nonmetastatic castration-resistant prostate cancer.
https://ift.tt/2KIk1rQ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου